Melbourne, Australia; 8 June 2021: Acrux Limited (ASX:ACR, “Acrux” or the “Company”) today announced that Almirall LLC has initiated patent litigation against Acrux in the U.S. District Court for the District of New Jersey, regarding the Company’s Paragraph IV Abbreviated New Drug Application (ANDA) for Dapsone Gel 7.5% (a generic version of Aczone® Gel, 7.5%), […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2021-06-08 04:41:492021-06-17 04:44:03Acrux confirms patent challenge for generic version of Aczone®
Link to Full Article Cambridge, UK, 7th June 2021: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that it has signed a formulation study agreement with Par Sterile Products, LLC, an Endo International plc company (“Par”). Under this agreement, Arecor will use its proprietary formulation technology […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2021-06-07 04:49:032021-06-17 04:56:40ARECOR EXCLUSIVE FORMULATION STUDY COLLABORATION WITH PAR STERILE PRODUCTS TO DEVELOP A STABLE READY TO USE PRODUCT
Melbourne, Australia; 4 June 2021: Acrux Limited (ASX:ACR, “Acrux” or the “Company”) is pleased to announce Mr Don Brumley has joined the Board as a Non-executive Director. Mr Brumley has 30 years’ experience as a senior partner of Ernst & Young, Oceania. He has extensive experience in IPOs, transactions and audit. Mr Brumley has advised […]
Link to Full Article Brighton, United Kingdom – 3rd June 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, announces that all resolutions proposed to shareholders at the Annual General Meeting held earlier today were duly passed. The full text of each resolution was included […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2021-06-03 05:06:222021-06-17 05:07:40Destiny Pharma Result of Annual General Meeting
Link to Full Article Data from Phase 2a Study Demonstrated Patients Treated with Auxora Experienced Reduced Severity of Acute Pancreatitis, Less Persistent Systemic Inflammatory Response Syndrome (SIRS) and More Rapid Restoration of Gut Function with Favorable Safety Profile Patient dosing has begun in Phase 2b study in acute pancreatitis; data expected H2 2022 LA JOLLA, […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2021-06-02 05:02:272021-06-17 05:03:37CalciMedica Publishes Positive Data from Phase 2a Study of Auxora in Patients with Acute Pancreatitis and Announces First Patients Dosed in Phase 2b Study
Link to Full Article MIP Diagnostics Ltd. has today shared the news that its COVID-19 nanoMIP outperforms commercial antibodies in a sensor platform, which could enable improved detection of lower viral loads during a wider infection period. Following the launch of its COVID-19 nanoMIP in April 2021, the business has worked with external collaborators to […]
Link to Full Article Melbourne, Australia – 1 June 2021: Adherium Limited (ASX: ADR), a leader in respiratory eHealth, remote monitoring and data management solutions, today announced submission to the US Food and Drug Administration (FDA) of a 510(k) clearance to market application for its first next generation Hailie® sensor with physiological measures for monitoring Asthma […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2021-06-01 04:46:472021-06-17 04:48:08Adherium submits US FDA 510(k) application for next generation Hailie® sensor with physiological measures
Link to Full Article Melbourne, Australia; 31 May 2021: As announced on 30 April 2021 Acrux Limited (ASX:ACR, “Acrux” or the “Company”) is pleased to confirm that the Company’s 100% owned investee company Acrux Pharma Pty Ltd has received approval from AusIndustry for an Advance and Overseas Finding application. The finding covers financial years 2018/19, […]
Link to Full Article Cambridge, United Kingdom – 27 May 2021 Congenica, the digital health company enabling rapid and accurate analysis of complex genomic data to transform people’s lives, has been featured in the UK’s Digital Health Playbook – ‘First 100’. An initiative by the Department of International Trade to highlight the nation’s most innovative and impactful digital health companies. The First 100 list features UK businesses with a proven track record of benefiting […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2021-05-27 05:28:172021-06-01 05:30:08Congenica named in UK’s Digital Health Playbook – ‘First 100’ Companies
Link to Full Article Brighton, United Kingdom – 19 May 2021 – Destiny Pharma plc (AIM: DEST) a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, as announced on 4 May 2021, will hold its 2021 Annual General Meeting (“AGM”) at the offices of finnCap Ltd, Destiny Pharma’s Nominated Advisor and […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2021-05-19 02:57:532021-06-04 02:59:09Destiny Pharma Notice to Register for 2021 AGM
Acrux confirms patent challenge for generic version of Aczone®
/in AcruxMelbourne, Australia; 8 June 2021: Acrux Limited (ASX:ACR, “Acrux” or the “Company”) today announced that Almirall LLC has initiated patent litigation against Acrux in the U.S. District Court for the District of New Jersey, regarding the Company’s Paragraph IV Abbreviated New Drug Application (ANDA) for Dapsone Gel 7.5% (a generic version of Aczone® Gel, 7.5%), […]
ARECOR EXCLUSIVE FORMULATION STUDY COLLABORATION WITH PAR STERILE PRODUCTS TO DEVELOP A STABLE READY TO USE PRODUCT
/in ArecorLink to Full Article Cambridge, UK, 7th June 2021: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that it has signed a formulation study agreement with Par Sterile Products, LLC, an Endo International plc company (“Par”). Under this agreement, Arecor will use its proprietary formulation technology […]
Acrux Announces Board Appointment
/in AcruxMelbourne, Australia; 4 June 2021: Acrux Limited (ASX:ACR, “Acrux” or the “Company”) is pleased to announce Mr Don Brumley has joined the Board as a Non-executive Director. Mr Brumley has 30 years’ experience as a senior partner of Ernst & Young, Oceania. He has extensive experience in IPOs, transactions and audit. Mr Brumley has advised […]
Destiny Pharma Result of Annual General Meeting
/in Destiny PharmaLink to Full Article Brighton, United Kingdom – 3rd June 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, announces that all resolutions proposed to shareholders at the Annual General Meeting held earlier today were duly passed. The full text of each resolution was included […]
CalciMedica Publishes Positive Data from Phase 2a Study of Auxora in Patients with Acute Pancreatitis and Announces First Patients Dosed in Phase 2b Study
/in CalcimedicaLink to Full Article Data from Phase 2a Study Demonstrated Patients Treated with Auxora Experienced Reduced Severity of Acute Pancreatitis, Less Persistent Systemic Inflammatory Response Syndrome (SIRS) and More Rapid Restoration of Gut Function with Favorable Safety Profile Patient dosing has begun in Phase 2b study in acute pancreatitis; data expected H2 2022 LA JOLLA, […]
MIP Diagnostics’ COVID-19 nanoMIP offers significantly improved sensitivity to antibodies in a diagnostic sensor
/in MIP DiagnosticsLink to Full Article MIP Diagnostics Ltd. has today shared the news that its COVID-19 nanoMIP outperforms commercial antibodies in a sensor platform, which could enable improved detection of lower viral loads during a wider infection period. Following the launch of its COVID-19 nanoMIP in April 2021, the business has worked with external collaborators to […]
Adherium submits US FDA 510(k) application for next generation Hailie® sensor with physiological measures
/in AdheriumLink to Full Article Melbourne, Australia – 1 June 2021: Adherium Limited (ASX: ADR), a leader in respiratory eHealth, remote monitoring and data management solutions, today announced submission to the US Food and Drug Administration (FDA) of a 510(k) clearance to market application for its first next generation Hailie® sensor with physiological measures for monitoring Asthma […]
Acrux Receipt of R&D Tax Incentive Rebate – Overseas Finding Application for Acrux Pharma Pty Ltd
/in AcruxLink to Full Article Melbourne, Australia; 31 May 2021: As announced on 30 April 2021 Acrux Limited (ASX:ACR, “Acrux” or the “Company”) is pleased to confirm that the Company’s 100% owned investee company Acrux Pharma Pty Ltd has received approval from AusIndustry for an Advance and Overseas Finding application. The finding covers financial years 2018/19, […]
Congenica named in UK’s Digital Health Playbook – ‘First 100’ Companies
/in CongenicaLink to Full Article Cambridge, United Kingdom – 27 May 2021 Congenica, the digital health company enabling rapid and accurate analysis of complex genomic data to transform people’s lives, has been featured in the UK’s Digital Health Playbook – ‘First 100’. An initiative by the Department of International Trade to highlight the nation’s most innovative and impactful digital health companies. The First 100 list features UK businesses with a proven track record of benefiting […]
Destiny Pharma Notice to Register for 2021 AGM
/in Destiny PharmaLink to Full Article Brighton, United Kingdom – 19 May 2021 – Destiny Pharma plc (AIM: DEST) a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, as announced on 4 May 2021, will hold its 2021 Annual General Meeting (“AGM”) at the offices of finnCap Ltd, Destiny Pharma’s Nominated Advisor and […]